Updated on 19 August 2026
Nose Cancer Vaccine
CEO at Grid Biosciences
China
About
Grid's nose cancer vaccine (against EBV) is currently in a Phase 1 clinical trial. The target market is a global opportunity of $31B USD, as validated by Merck's $922.5M and Lilly's $1.55B EBV deal. Grid is targeting Phase 2 and its strategic options.
Project Location
- United States
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Technology
Technology
- Bio-Tech
Type(s) of Last Financing Round of the project (if Applicable)
- Equity (private)
Main Service(s) Required
- Financial Services
Organisation
China (Hong Kong)
Similar opportunities
Project
Focused Ultrasound for Next-Generation Radiotherapy
- No
- Yes
- Technology
- Private Project
- Equity (private)
- Financial Services
- Investment / Financing Discussion
Carmen Ng
CEO at CAPRiser Group
Canada
Project
- No
- No
- Equity
- Bio-Tech
- Technology
- Hedge Funds
- Private Project
- Health Technology
- Convertible Loan
- Medical Technology
- Financial Services
- Venture Capital (VC)
- Mergers & Acquisition
- Direct Equity Investment
- Private Equity & Venture Capital
- Investment / Financing Discussion
Andrea Chicca
Chief Executive Officer at Synendos Therapeutics AG
Switzerland
Project
- Yes
- Yes
- Bio-Tech
- Technology
- Private Project
- Health Technology
- Health Facilities
- Medical Technology
- Financial Services
- Government & Public Funding
- Investment / Financing Discussion
Fung Ki Leung
Research and Development Scientist at Ynno Med Limited
China (Hong Kong)